Biocon Ltd
NSE:BIOCON
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of
Biocon Ltd (BIOCON) under the Base Case is 369.35 INR per share.
Compared with the current market price of 364.4 INR, the stock appears
Undervalued by 1% .
The intrinsic value is calculated using the DCF method. The model assumes net margin rises from 2.3% last year to 8.1% by 2042, above its five-year average of 5.6%. Revenue grows about 13% a year over the next five years, below its five-year pace of 19%. The value of the years after 2042 is tied to revenue, so margins count only until then.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Biocon Does
Biocon Ltd is a biopharmaceutical company that develops and makes medicines for diabetes, cancer, and other long-term illnesses. It sells a mix of biologic drugs, biosimilars, generic formulations, and key ingredients used by other drug makers. The company also works in contract research and development through its services businesses, which support drug discovery and testing for other pharmaceutical firms.
- Headquarters
- India IN
- Employees
- 16 420
- IPO date
- Apr 17, 2004
Biocon has a narrow economic moat
Biocon Ltd has a narrow economic moat, offering limited protection against competitors and some ability to sustain profitability.
Read the full moat analysisBalance Sheet
Recent Events
Latest Earnings Call
Biocon framed the second half as an execution inflection, with biosimilar momentum, improving generics profitability and a recovering Syngene trajectory supporting commercial acceleration.
Open the earnings call- EPS
- ₹0.29
- Expected
- ₹1.04
- Surprise
- −72.1%
- Stock, day of the call
- +0.4%
Past 12 months
Continue BIOCON Research
Decided on Biocon? Get an email when BIOCON reaches the price you’d buy at. Free with an account.
Other Biocon listings
What is the Intrinsic Value of one BIOCON stock?
The intrinsic value for
Biocon Ltd (BIOCON) under the Base Case is 369.35 INR.
Is BIOCON stock undervalued or overvalued?
Compared with the current market price of 364.4 INR, the stock appears Undervalued by 1% .